Integrative Cancer Therapies (Sep 2023)

Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash

  • Won Kil Lee PhD,
  • Jisoo Myong KMD, PhD,
  • Eunbin Kwag MS,
  • Younmin Shin MS,
  • Ji Woong Son MD, PhD,
  • Byong Chul Yoo PhD,
  • Byoung-Soo Kim KMD, PhD,
  • Hwa-Seung Yoo KMD, PhD,
  • Jeong June Choi PhD

DOI
https://doi.org/10.1177/15347354231198090
Journal volume & issue
Vol. 22

Abstract

Read online

Erlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC) patients yet it causes severe side effects such as skin rash. In this study, researchers compared the untargeted compound profiles before and after erlotinib administration to observe changes in blood metabolites in NSCLC patients. The levels of 1005 substances changed after taking erlotinib. The levels of 306 and 699 metabolites were found to have increased and decreased, respectively. We found 5539 substances with peak area differences based on the presence of skin rash. Carbohydrate, amino acid, and vitamin metabolic pathways were altered in response to the onset of erlotinib-induced skin rash. Finally, this study proposed using plasma metabolites to identify biomarker(s) induced by erlotinib, as well as target molecule(s), for the treatment of dermatological toxic effects.